OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Choueiri on the Role of Cabozantinib in RCC

October 10th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Dr. Luke on Impactful Data in the Field of Melanoma

October 10th 2017

Jason Luke, MD, an assistant professor of medicine at the University of Chicago Medicine, discusses impactful data in the field of melanoma.

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

October 10th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Dr. Muss on Determining Treatments for HER2+ Breast Cancer

October 10th 2017

Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

Dr. Callander on Treatment Considerations in Multiple Myeloma

October 10th 2017

Natalie S. Callander, MD, professor of medicine at the Division of Hematology/Oncology, University of Wisconsin Carbone Cancer Center, discusses treatment considerations in relapsed and refractory multiple myeloma.

Dr. Maloney on Challenges With CAR T-Cell Therapy in ALL

October 10th 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses the challenges that exist in the use of CAR T-cell therapy in acute lymphocytic leukemia.

Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

October 8th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

Dr. Hensing Discusses Studies in Stage III NSCLC

October 7th 2017

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses prospective studies in stage III non-small cell lung cancer (NSCLC).

Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

October 7th 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

Dr. Villaflor Discusses Alectinib in ALK+ NSCLC

October 5th 2017

Victoria Villaflor, MD, associate professor of medicine, Robert H. Lurie Comprehensive Cancer Center, discusses alectinib (Alecensa) in patients with ALK-positive non–small cell lung cancer.

Dr. Forster Discusses the ATLANTIS Study in Small-Cell Lung Cancer

October 5th 2017

Martin Forster, MD, medical oncologist, University College London Hospitals, discusses the ATLANTIS study in small-cell lung cancer.

Dr. Patel Discusses Checkpoint Blockade in NSCLC

October 5th 2017

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses checkpoint blockade in non–small cell lung cancer.

Dr. Uzzo on Unmet Needs in Kidney Cancer

October 4th 2017

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.

Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

October 4th 2017

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

Dr. Welling on the Efficacy of Nivolumab in HCC

October 4th 2017

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Dr. Zamarin on the Role of Vaccines in Cervical Cancer

October 3rd 2017

Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of vaccines for patients with cervical cancer.

Dr. Hofmeister on the Treatment of Patients with Newly Diagnosed Myeloma

October 3rd 2017

Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses the treatment of patients with newly diagnosed multiple myeloma.

Dr. Ginsburg on Genetic Testing Guidelines for Gynecologic Malignancies

October 3rd 2017

Ophira M. Ginsburg, MSc, MD, FRCPC, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses genetic testing for patients with gynecologic cancers.

Dr. Awan Discusses Venetoclax in CLL

October 3rd 2017

Farrukh Awan, MBBS, associate professor, The Ohio State University Comprehensive Cancer Center, discusses venetoclax (Venclexta) in chronic lymphocytic leukemia.

Dr. Hensing on the Management of Stage III NSCLC

October 3rd 2017

Thomas A. Hensing, MD, co-director of the Thoracic Oncology Program at NorthShore University HealthSystem, discusses the management of patients with stage III non–small cell lung cancer (NSCLC).